Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

A dominant trend is the increasing use of GLP-1 receptor agonists like semaglutide and tirzepatide, which have demonstrated ... The region also boasts a strong pipeline of clinical trials aimed at ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Tirzepatide has emerged as the most effective treatment for lowering blood sugar and promoting weight loss in people with ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...